KR20200098615A - 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체 - Google Patents

사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체 Download PDF

Info

Publication number
KR20200098615A
KR20200098615A KR1020207020090A KR20207020090A KR20200098615A KR 20200098615 A KR20200098615 A KR 20200098615A KR 1020207020090 A KR1020207020090 A KR 1020207020090A KR 20207020090 A KR20207020090 A KR 20207020090A KR 20200098615 A KR20200098615 A KR 20200098615A
Authority
KR
South Korea
Prior art keywords
lysine
ala
leu
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207020090A
Other languages
English (en)
Korean (ko)
Inventor
레이몬드 슈흐
키아라 인디아니
Original Assignee
콘트라펙트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘트라펙트 코포레이션 filed Critical 콘트라펙트 코포레이션
Publication of KR20200098615A publication Critical patent/KR20200098615A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207020090A 2017-12-12 2018-12-12 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체 Ceased KR20200098615A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762597577P 2017-12-12 2017-12-12
US62/597,577 2017-12-12
US201862721969P 2018-08-23 2018-08-23
US62/721,969 2018-08-23
PCT/US2018/065265 WO2019118632A1 (en) 2017-12-12 2018-12-12 Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
KR20200098615A true KR20200098615A (ko) 2020-08-20

Family

ID=66819724

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020090A Ceased KR20200098615A (ko) 2017-12-12 2018-12-12 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체

Country Status (11)

Country Link
US (1) US12121568B2 (https=)
EP (1) EP3723789A4 (https=)
JP (2) JP2021506769A (https=)
KR (1) KR20200098615A (https=)
CN (1) CN111971058A (https=)
AU (1) AU2018384790C1 (https=)
BR (1) BR112020011433A2 (https=)
CA (1) CA3085644A1 (https=)
IL (2) IL303122A (https=)
MX (1) MX2020006098A (https=)
WO (1) WO2019118632A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118632A1 (en) 2017-12-12 2019-06-20 Contrafect Corporation Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
WO2019126670A1 (en) * 2017-12-22 2019-06-27 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US10988520B2 (en) 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN114040773A (zh) * 2019-04-05 2022-02-11 康特拉费克特公司 在存在人血清的情况下对铜绿假单胞菌具有杀菌活性的溶素及其衍生物
KR102225240B1 (ko) * 2019-07-03 2021-03-10 경북대학교 산학협력단 다제내성 병원성 세균을 효과적으로 사멸시키는 재조합 항균 단백질 Ablysin의 용도
EP4058468A4 (en) * 2019-11-14 2024-04-10 Contrafect Corporation POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF
US20250324979A1 (en) * 2021-09-03 2025-10-23 Alexandre Ismail LysECD7 VARIANTS AND METHODS OF USING THE SAME
CN114410670B (zh) * 2022-01-29 2024-01-23 福建医科大学附属口腔医院 一种溶菌酶及其在口腔护理用品中的应用
CN117660413B (zh) * 2023-12-15 2024-06-07 华南理工大学 一种内溶素Lys009及其工程改造和应用
CN120173923A (zh) * 2025-05-08 2025-06-20 浙江大学 与PeiR裂解酶高维特征同源的产甲烷菌裂解酶及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
AU2010211456B2 (en) 2009-02-06 2016-05-26 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Antibacterial phage, phage peptides and methods of use thereof
CA2780079A1 (en) 2009-11-18 2011-05-26 Basf Plant Science Company Gmbh Process for the production of fine chemicals
SG184836A1 (en) 2010-04-27 2012-11-29 Lysando Ag Method of reducing biofilms
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
DK2699253T3 (en) 2011-04-21 2018-07-16 Univ Rockefeller STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
WO2015200783A2 (en) 2014-06-26 2015-12-30 The Rockefeller University Acinetobacter lysins
EP4115897A1 (en) * 2015-09-17 2023-01-11 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
WO2019118632A1 (en) 2017-12-12 2019-06-20 Contrafect Corporation Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
CN108103050A (zh) 2018-02-11 2018-06-01 中国医药集团总公司四川抗菌素工业研究所 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3840771A4 (en) 2018-08-23 2023-04-19 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Also Published As

Publication number Publication date
CN111971058A (zh) 2020-11-20
US20210085758A1 (en) 2021-03-25
US12121568B2 (en) 2024-10-22
CA3085644A1 (en) 2019-06-20
IL303122A (en) 2023-07-01
EP3723789A4 (en) 2021-12-01
JP2021506769A (ja) 2021-02-22
AU2018384790C1 (en) 2025-05-01
JP7646237B2 (ja) 2025-03-17
IL275060A (en) 2020-07-30
JP2024010053A (ja) 2024-01-23
BR112020011433A2 (pt) 2020-12-01
WO2019118632A1 (en) 2019-06-20
IL275060B1 (en) 2023-06-01
MX2020006098A (es) 2020-08-24
AU2018384790B2 (en) 2024-10-17
RU2020118691A (ru) 2022-01-13
AU2018384790A1 (en) 2020-07-30
EP3723789A1 (en) 2020-10-21
IL275060B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
JP7646237B2 (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
US20240018192A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN108348574B (zh) 具有对抗革兰氏阴性菌的活性的溶素多肽
US20220402984A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
KR20210049023A (ko) 리신-항미생물 펩타이드(amp) 폴리펩타이드 작제물, 리신, 이를 인코딩하는 단리된 폴리뉴클레오타이드 및 이의 용도
JP2021513865A (ja) 修飾ＰｌｙＳｓ２溶解素及びその使用
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
KR20210148320A (ko) 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체
KR20230162045A (ko) 그램-음성 박테리아에 대해 활성인 아무린, 리신, 및 리신-항미생물 펩타이드 (amp) 작제물
US20220411473A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
WO2020093057A1 (en) Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601